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Introduction
Accidents and disease have increased at a constant and steady 
rate alongside the growth of industrial development and the use 
of chemicals. Due to this, a policy to limit the use of chemicals is 
being implemented throughout the world.  
Following this trend, South Korea (hearafter Korea) is plan-
ning to pass the Korean Registration Evaluation Authorization 
and Restriction of Chemicals (REACH), which is based on risk 
assessment that not only looks at the hazards of chemicals but 
also the risk of exposure, and this is planned to be implemented 
from 2015. 
It follows that there should be proper support provided in or-
der to regulate chemical use through policing the usage and lim-
itation of chemicals.
Cost-benefit analysis is an important factor in analysis and de-
cision-making and is an important policy decision tool in many 
countries. The cost element comprises a variety of costs and can 
be divided into direct and indirect costs. Direct costs are made 
up of compliance costs, government regulation costs, social wel-
fare costs, and relocation costs. The benefit element refers to the 
positive effect towards improving social members’ welfare and 
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is regulated and reformed by policy. 
According to the introduction of REACH by the European 
Union (EU), the estimation of benefits related to health is stud-
ied in two parts. One part is the effect of health improvement on 
workers in the workplace and the other part is the effect of 
health improvement on the public
The effect of health improvement for workers in the work-
place, Risk and Policy Analysts Ltd., is estimated to incur a cost 
of 176 to 544 hundred million euros, which will cover five dis-
eases, including occupational cancer [2]. The effect of the 
health improvement of the public is estimated to incur a cost of 
about a 224 to 513 hundred million euros. According to Pearce 
and Koundouri [1], when considering the reduction in medical 
costs the estimated figure was 48 to 201 hundred million euros 
and, furthermore [3], the European Commission estimates that 
the benefit from REACH will amount to the value of about 500 
hundred million euros within 30 years.
There is a domestic study by Bae [4] that states that the esti-
mated benefit from the Korea REACH act, based on the cost of 
work related diseases and preventable occupational disease cal-
culates a medical cost of 15.35 million Korean won (KRW) per 
1 unit of disability-adjusted life year in the national healthcare 
expenditure reduction.
With regards to the effects of chemicals on the body, the bene-
fit analysis divides the benefits into cancer death benefit and the 
burden of disease benefit. 
When we estimate the benefit through analysis of disease 
there is a premise that the disease will not necessarily lead to 
death. The benefit also estimates how much the environment 
policy can influence disease remission and its economic worth.
This study is specifically conducted to estimate the cost paid 
by the public suffering from diseases possibly caused by chemi-
cals, and to check the effect on public health. 
Materials and Methods
Cost-of-illness (COI), which is one of the effective benefit esti-
mation methods for disease, is widely used in health and medical 
areas as a methodology for measuring the socioeconomic COI. 
COI, which can be said to be a kind of scale-based analysis 
method, estimates the potential value lost through illness as a 
monetary unit and calculates the cost in terms of direct, indirect 
and psychological costs. 
The key advantage of COI is that it is easily available, uses reli-
able materials, and provides an exact sensitivity analysis to mea-
sure a material’s change in order to calculate social costs.
In the cost of disease, direct costs such as direct medical cost 
refer to real treatment costs, such as treatment, cure, and long-
term treatment and indirect medical costs refer to elements in 
recovery, such as subsidiary nursing fees for treatment and 
transportation fees paid by patients visiting healthcare centers. 
Indirect costs are the productivity loss occurring as a result of 
death or disease. Psychological costs are related to the pain or 
low quality of life suffered by the patients, family, or friends. 
However, this is excluded in the disease cost estimation because 
the cost is difficult to quantify [5, 6]. 
This study estimates direct medical costs, transportation fees 
for hospitalization and outpatient treatment, and nursing fees 
through those patients suffering from diseases caused by chemi-
cal in order to analyze the COI, taking into account the cost of 
productivity loss as an indirect cost. The list of cost items are 
shown in Table 1.
Results
To calculate the medical expenses of diseases possibly related 
to certain chemicals, international organizations, non-Korean 
environment analysis for disease, as well as domestic environ-
mental disease health experts and relevant stakeholders selected 
some diseases through the Delphi survey. Some 298 diseases, 
divided into the 21 areas, are classified by the National Health 
Insurance Service of Korea [7].
Seventeen hundred experts connected with contaminant man-
agement technology, risk management and toxicity evaluation 
conducted a survey by e-mail. A total of 71 people responded to 
the survey (response rate 4.2%), and the result of the survey was 
medically reviewed by doctors of family medicine. 
The diseases possibly caused by chemicals were divided into 
16 categories except for neoplasm diseases, infectious diseases, 
external cause diseases, below 10% of expert’s response rate, and 
disease not connected with chemicals. 
Of the 298 diseases, the Korean Standard Classification of 
Diseases excluded those not related to chemicals. The Delphi 
survey, about environmental disease caused by chemicals, was 
conducted by environmental and health experts.   
None of the diseases received any response. There were plenty 
Table 1. List of cost items   
Item Details Reference
Medical cost Direct medical  
 cost
Cost-sharing
Medical insurance expenses 
 per one person/case
7
Indirect medical  
 cost
Transportation fees  
Nursing fees
8,10
Cost of productivity loss 
  (classification of outpatient and  
 inpatient)
Daily labor costs  
Average days to medical  
treatment
9
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of answers regarding respiratory organs (about 96%) and integ-
umentary systems, but there was a low response rate regarding 
diseases connected to the ear and tuberculosis.  
An analysis conducted by experts excluded diseases, including 
vitamin A deficiency, varicose veins, paralytic ileus and intestinal 
obstruction without hernia, diverticulosis, redundant prepuce, 
phimosis and paraphimosis, dystocia, congenital infection and 
parasitic diseases, malnutrition, other hernia, female genital pro-
lapse, postpartum bleeding, other tuberculosis, inguinal hernia, 
other dorsopathies, single spontaneous delivery, birth trauma, 
acquired deformities of limb, other articular disorders, and lum-
bar and other Intervertebral disc disorder.
Also any disease caused by neoplasm leading to death is not con-
sidered as an environmental disease caused by chemicals. 
Annual medical expenses for one person are calculated with pa-
tients and insurance corporations sharing the costs, which are 
based on treatment costs for illnesses possible caused by chemicals. 
Medical costs were calculated separately for inpatients and 
outpatients and comprised the cost of treating a patient and the 
price of drugs. 
In the case of nursing fees included in indirect medical costs for 
inpatients, the patients suffer a loss of earnings because some-
one, such as an immediate family member or relative, has to care 
for inpatients if they don’t hire a caregiver. Nursing fees can be 
estimated on an average daily cost of 33500 KRW, based on the 
Ministry of Health and Welfare’s announcement in 2010 [8]. 
Spending on the average round-trip transportation fare for 
healthcare center visits is based on the health panel survey mate-
rial of 2010. Inpatients average a transportation fare of 7597 
KRW (including guardian transportation fare), which is multi-
plied with number of round-trips. In the case of outpatients, 
their one-off transportation fare, 777 KRW, is also multiplied in 
the case of a number of round-trips [10]. 
There is not enough statistical material regarding the number 
of hospitalizations, so when calculating the transportation fee, 
the average number of hospitalizations by age in the Korean 
Health Panel survey of Korea Institute for Health and Social Af-
fairs of 2011 is used. In the case of hospitalization, the transpor-
tation fee is multiplied by 2 (patient and protector).
In the case of transportation fees and nursing fees, there is no 
statistical material for disease available from the National Health 
Insurance Service of Korea for the baseline year 2012. Therefore 
the fees for transportation and nursing were corrected according 
to the price equivalent index of 2010. The cost of productivity 
loss as an indirect cost estimates economical productive capacity 
loss. Generally, the estimation measures productivity loss when 
a worker with a disease can’t work or it affects their workplace. 
When the work is temporarily stopped, the cost is calculated by 
multiplying lost time by the daily wage. Productivity loss also 
contains not only lost time through nursing but also lost work in 
the workplace. Productivity loss costs estimate annual produc-
tivity loss, cost of a lost work period through disease, taking into 
account the economically active population survey materials, 
such as work days, working hours, the monthly salary and the 
average income in the yearbook of employment and labor statis-
tics of the Ministry of Employment and Labor [9]. 
The legal working age in Korea is 15 years old. The cost of pro-
ductivity loss is estimated based on an economically active pop-
ulation related to age and the number of patients related to age 
(over 15 years old).  The COI estimation is shown in Table 2. 
As a result, the calculated cost of all of the diseases selected in 
2012 is 77 million KRW per person. The direct and indirect 
costs being 52 million KRW and 23 million KRW, respectively. 
In the total disease cost, mental and behavioral disability costs 
amount to 16 million KRW, relevant blood immunological pa-
rameters costs are 7.4 million KRW, and diseases of the nervous 
system costs are 6.7 million KRW. 
Direct costs were calculated for mental and behavioral disabili-
ty (9.6 million KRW), relevant blood immunological parame-
ters (6.4 million KRW), and the circulatory system (4.8 million 
KRW). Indirect costs were mental and behavioral disability (6.9 
million KRW), diseases of the nervous system (2.1 million 
KRW) and tuberculosis (1.8 million KRW).
In conclusion, this study estimates the costs of diseases con-
tracted from harmful chemicals by applying COI. 
One social benefit of the support regulation policy is the cal-
culation of every single person’s satisfaction and welfare in terms 
of monetary value. However, it is too difficult to calculate the 
benefit of environmental policy by comparison with the general 
economic policy. 
Table 2. Cost-of-illness estimation 
Item Details
Direct medical cost ∑(treatment amount×patients)
Indirect medical cost Transportation costs=(average visit days×average one-way transportation costs)+(average number of hospitalization  
 × average one-way transportation costs)
Nursing costs=hospitalization days per patients×1 day average wage
Cost of productivity loss 
 (classification of outpatient and inpatient)
(∑inpatients×daily labor costs×visiting days [inpatients]×labor force participation rate) 
 +(∑outpatients×daily labor costs×visiting days [outpatients]*0.5×labor force participation rate)
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Therefore, in order to establish a level of usage and restriction 
of chemicals, there should be a cost-benefit analysis and the re-
sults of this analysis are needed to be supported with examples.   
This study conducted a survey conducted by experts regard-
ing diseases possibly caused by chemicals and estimates the dis-
ease cost for the general public. The results of this study can be 
used to formulate a basic report for a socioeconomic evaluation 
on the permitted use of chemicals and limits of usage. 
In the future, we plan to undergo a peer review but a study of 
illness due to chemicals derived through a causal relationship 
study of the chemical and diseases is needed. 
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